Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) (NCT06607549)
A Phase 1 Study of Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (31 items) and avoid the listed exclusions (21 items).
Location: Sidney Kimmel Comprehensive Cancer Center at Jefferson — Philadelphia, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Concurrent use of other approved or investigational antineoplastic agents (with the exception of corticosteroids).
- History of intracranial hemorrhage or clinically significant stroke within 6 months prior to enrollment
- History of prior radiation to the CNS.
- Significant medical diseases or conditions, as assessed by the investigator, that would substantially increase the risk-to-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction in the past 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, severely immunocompromised state, and congestive heart failure, New York Heart Association Class III-IV.
- Known bleeding diathesis (e.g., von Willebrand's disease), hemophilia, or active bleeding.
- Known Human immunodeficiency virus (HIV) infection.
- Prior allogeneic stem cell transplant for lymphoma (autologous stem cell transplant is NOT an exclusion).
- Prior exposure to loncastuximab tesirine
- Chemotherapy or targeted small molecule therapy (or other therapy for CNS lymphoma) within 3 weeks prior to the first day of Lonca-R (or 5 half-lives (whichever is shorter), or 2 weeks prior to the first day of Lonca-R for monoclonal antibodies.
- The patient must have recovered to baseline or ≤ grade 1 from prior toxicities of therapy with the exception of alopecia and myelosuppression provided lab criteria met. Recovery to ≤ grade 2 neuropathy is permitted.
- Cellular therapy (CAR-T or Bispecific antibodies) within 8 weeks.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (3 Sites)
- Sidney Kimmel Comprehensive Cancer Center at Jefferson — Philadelphia, Pennsylvania
- Brown University Health Rhode Island Hospital — Providence, Rhode Island
- Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (801) 585-0115
Email: Rachel.Kingsford@hci.utah.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Central Nervous System Lymphoma
- Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies — Houston, Texas
- LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma — Birmingham, Alabama
- Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) — Bethesda, Maryland
- A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas — Tampa, Florida
- Acalabrutinib in CNSL — Boston, Massachusetts
Explore by condition: All Central Nervous System Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.